Gastric cancer, also known as stomach cancer, originates in the stomach. The most common type, called adenocarcinoma, begins ...

New research shows that ENHERTU (trastuzumab deruxtecan) could change the standard of care treatment for metastatic HER2 positive breast cancer patients. The trial compared ENHERTU and Kadcyla, the ...

“I look after myself as much as I can. I diet and exercise. I'm terribly lazy about exercising,” the English actress admitted, “but I do believe that diet plays an enormous part in our health.” Mills, ...

There are no screening tests for lymphoma, because no test has been proven to improve survival Learn whether you’re at risk and watch for symptoms such as swollen lymph nodes, weight loss, night ...

The Food and Drug Administration (FDA) has just approved Novartis’ Kisqali (ribociclib) in combination with an aromatase inhibitor as treatment for people with HR+/HER2- stage II and III early breast ...

The 58-year-old wife of actor Terry Crews, Rebecca, battled stage one breast cancer four years ago with resilience and determination because “you gotta go through the valley, not stop in the middle,” ...

When a doctor suspects a patient may have a glioma, they will perform a thorough workup to get an accurate diagnosis in order to tailor treatment to the patient and cancer. The first step is a ...

The ketogenic diet is very low in carbohydrates and very high in fat, with a moderate amount of protein. Cancer cells collect energy from glucose, and the goal of the keto diet is to limit the amount ...

Imagine being told you looked great because you’ve lost weight during cancer treatments. That’s exactly what happened to the world’s first plus-size supermodel, Emme, 56, after she was diagnosed with ...

Oswald Peterson, 54, is a stage four lung cancer survivor who has been cancer free after receiving treatment with a game changing class of drugs called checkpoint inhibitors (or PD-L1 inhibitors), ...

Only some lung cancer patients benefit, especially those with PD-L1 protein on their cells, as it responds well to immunotherapy. Clinical trials are exploring new targets beyond PD-L1, potentially ...